Evidence map›Paper›PMID 35068087›Full record

Trial reportNeuropsychopharmacology reports2022

Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial.

Hiroko Kotajima-Murakami, Ayumi Takano, Shinya Hirakawa, Yasukazu Ogai, Daisuke Funada, Yuko Tanibuchi, Eriko Ban, Minako Kikuchi, Hisateru Tachimori, Kazushi Maruo and 6 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Hiroko Kotajima-MurakamiAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Ayumi TakanoDepartment of Drug Dependence Research, National Institute of Mental Health, National Centre of Neurology and Psychiatry, Tokyo, Japan.
Shinya HirakawaDepartment of Clinical Data Science, Clinical Research & Education Promotion Division, National Centre of Neurology and Psychiatry, Tokyo, Japan.
Yasukazu OgaiSocial Psychiatry and Mental Health, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Daisuke FunadaDepartment of Psychiatry, National Centre Hospital, National Centre of Neurology and Psychiatry, Tokyo, Japan.ORCID 0000-0001-5228-4699
Yuko TanibuchiDepartment of Drug Dependence Research, National Institute of Mental Health, National Centre of Neurology and Psychiatry, Tokyo, Japan.ORCID 0000-0002-1690-6793
Eriko BanDepartment of Drug Dependence Research, National Institute of Mental Health, National Centre of Neurology and Psychiatry, Tokyo, Japan.
Minako KikuchiDepartment of Drug Dependence Research, National Institute of Mental Health, National Centre of Neurology and Psychiatry, Tokyo, Japan.
Hisateru TachimoriDepartment of Clinical Data Science, Clinical Research & Education Promotion Division, National Centre of Neurology and Psychiatry, Tokyo, Japan.ORCID 0000-0001-6401-2885
Kazushi MaruoDepartment of Biostatistics, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Takahiro KawashimaDepartment of Clinical Data Science, Clinical Research & Education Promotion Division, National Centre of Neurology and Psychiatry, Tokyo, Japan.
Yui TomoDepartment of Clinical Data Science, Clinical Research & Education Promotion Division, National Centre of Neurology and Psychiatry, Tokyo, Japan.
Tsuyoshi SasakiDepartment of Child Psychiatry, Chiba-University Hospital, Chiba, Japan.
Hideki OiDepartment of Clinical Research Promotion, Translational Medical Centre, National Centre of Neurology and Psychiatry, Tokyo, Japan.
Toshihiko MatsumotoDepartment of Drug Dependence Research, National Institute of Mental Health, National Centre of Neurology and Psychiatry, Tokyo, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID 0000-0001-8342-0278
National Center of Neurology and Psychiatry · JPNational Institute of Mental Health · JPNational Cancer Centre Japan · JPTokyo Metropolitan Institute of Medical Science · JPUniversity of Tsukuba · JPChiba Hospital · JPChiba University Hospital · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimNo effective pharmacological interventions have been developed for patients with methamphetamine use disorder. Ifenprodil is a blocker of G protein-activated inwardly rectifying potassium channels, which play a key role in the mechanism of action of addictive substances. We conducted a randomized, double-blind, exploratory, dose-ranging, placebo-controlled trial to examine the clinical efficacy of ifenprodil for the treatment of methamphetamine use disorder.

methodsParticipants were assigned to three groups: placebo, 60 mg/d ifenprodil, or 120 mg/d ifenprodil. The drug administration period was 84 days. The primary outcome was the use or nonuse of methamphetamine during the drug administration period in the placebo group vs 120 mg/d ifenprodil group. We also assessed drug use status, relapse risk based on the Stimulant Relapse Risk Scale (SRRS), drug craving, and methamphetamine in urine as secondary outcomes. We further evaluated drug use status and SRRS subscale scores in patients who were not taking addiction medications during the study.

resultsIfenprodil did not affect the primary or secondary outcomes. However, the additional analyses showed that the number of days of methamphetamine use during the follow-up period and scores on the emotionality problems subscale of the SRRS improved in the 120 mg/d ifenprodil group. The safety of ifenprodil was confirmed in patients with methamphetamine use disorder.

conclusionThe present findings did not confirm the efficacy of ifenprodil for methamphetamine use disorder treatment based on the primary or secondary outcomes, but we found evidence of its safety and efficacy in reducing emotionality problems. CLINICAL

trial registrationThe study was registered at the University Hospital Medical Information Network Clinical Trial Registry (no. UMIN000030849) and Japan Registry of Clinical Trials (no. jRCTs031180080). The main registration site is jRCT (https://jrct.niph.go.jp/).

Indexed as

Central Nervous System StimulantsMethamphetamineDouble-Blind MethodHumansPiperidinesCentral Nervous System StimulantsifenprodilMethamphetaminePiperidinesdays of methamphetamine useG protein-activated inwardly rectifying potassium channelifenprodilmethamphetamine use disorderrandomized-controlled trial

Identifiers

PMID35068087
PMCPMC8919120
OpenAlexW4206994965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.